Application of liquid chromatography-mass spectrometry for the determination of semaglutide in human serum in clinical pharmacokinetic studies DOI Creative Commons
P. K. Karnakova, Е. S. Vetrova, P. A. Karpova

и другие.

Meditsinskiy sovet = Medical Council, Год журнала: 2024, Номер 16, С. 246 - 255

Опубликована: Ноя. 1, 2024

Introduction . Semaglutide preparations are an important therapeutic option for patients suffering from type 2 diabetes mellitus and obesity due to their high efficacy the expected increase in prevalence of these diseases. Consequently, there is a growing need development domestic analogs semaglutide requiring bioequivalence studies. This study proposes use high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) as alternative widely used immunoassay quantitative determination human serum. Aim To develop validate method serum using HPLC-MS/MS. Materials methods Serum sample preparation was based on protein precipitation acetonitrile-methanol mixture. Liraglutide selected internal standard. The mobile phase consisted 0.3% formic acid water acetonitrile. stationary represented by Phenomenex Kinetex C18 chromatographic column 100×3.0 mm, 5 μm, 100 Å. Ionization liraglutide performed positive electrospray mode. Detection carried out multiple reaction monitoring mode (MRM). Results demonstrated accuracy precision, relative error standard deviation values less than 15% across all quality control levels. confirmed analytical ranges were 0.50–200.00 ng/mL 1.00–800.00 ng/mL. Over 3.400 volunteer samples analyzed part Compared ELISA method, proposed provides higher selectivity reproducibility measurements. Conclusions has been developed that reproducible blood validated accordance EAEU requirements successfully applied studies GP40331 (GEROPHARM LLC, Russia). suitable conducting pharmacokinetic other preparations.

Язык: Английский

How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense? DOI Creative Commons
Ralf Weiskirchen, Amedeo Lonardo

British Journal of Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 13, 2025

Obesity is a complex and growing global concern, affecting one in eight individuals compromising health, quality of life expectancy. It carries significant metabolic, cardiovascular, oncological, hepatorenal, skeletal psychiatric risks, imposing substantial costs on health‐care systems. Traditional treatments have often been ineffective or led to relapse after lifestyle changes. Whereas bariatric surgery effective, it also involves risks such as mortality hospitalisation. Semaglutide, licensed 2018, synthetic analogue glucagon‐like peptide 1 which regulates glucose metabolism gastrointestinal (GI) motility. Studies show that semaglutide, administered either weekly subcutaneously, daily orally, induces an average weight loss −11.62 kg compared placebo reduces waist circumference by up −9.4 cm. improves blood pressure, fasting levels, C‐reactive protein levels lipid profiles. The most common adverse events are mild‐to‐moderate GI complaints occurring more frequently with administration than doses; hypoglycaemia without intervention. Weight regain follows semaglutide withdrawal. Furthermore, offers cardiovascular benefits for patients established atherosclerotic disease (CVD), lowers the risk kidney outcomes cardiovascular‐related death, resolves nonalcoholic steatohepatitis many cases, positively impacts mental health life. In conclusion, therapy could significantly benefit adults regarding CVD if made widely accessible. Ethical financial considerations must be addressed personalised obesity treatment approaches.

Язык: Английский

Процитировано

3
GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review DOI Creative Commons

Candace Jarade,

Tetiana Zolotarova,

Areesha Moiz

и другие.

EClinicalMedicine, Год журнала: 2024, Номер 75, С. 102789 - 102789

Опубликована: Авг. 15, 2024

Язык: Английский

Процитировано

4
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment DOI Creative Commons

Richard Salvador,

Carla Moutinho, Carla Silva

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(3), С. 399 - 399

Опубликована: Март 12, 2025

This review addresses the role of semaglutide (SMG), a GLP-1 receptor agonist, in treatment obesity and its related comorbidities. Originally developed for type 2 diabetes (DM2), SMG has shown significant efficacy weight reduction, with superior results compared to other treatments same class. Its effects include appetite suppression, increased satiety, improvements cardiovascular, renal, metabolic parameters. Studies such as SUSTAIN, PIONEER, STEP highlight superiority agonists anti-obesity drugs. The oral formulation showed promising initial results, higher doses (50 mg) showing losses comparable those subcutaneous administration. Despite benefits, there are challenges, regain after cessation treatment, gastrointestinal adverse effects, variability response. Future studies should explore strategies mitigate these identify predictive factors efficacy, expand therapeutic indications conditions insulin resistance. constant innovation this class drugs reinforces potential transform protocols chronic weight-related diseases.

Язык: Английский

Процитировано

0
Application of liquid chromatography-mass spectrometry for the determination of semaglutide in human serum in clinical pharmacokinetic studies DOI Creative Commons
P. K. Karnakova, Е. S. Vetrova, P. A. Karpova

и другие.

Meditsinskiy sovet = Medical Council, Год журнала: 2024, Номер 16, С. 246 - 255

Опубликована: Ноя. 1, 2024

Introduction . Semaglutide preparations are an important therapeutic option for patients suffering from type 2 diabetes mellitus and obesity due to their high efficacy the expected increase in prevalence of these diseases. Consequently, there is a growing need development domestic analogs semaglutide requiring bioequivalence studies. This study proposes use high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) as alternative widely used immunoassay quantitative determination human serum. Aim To develop validate method serum using HPLC-MS/MS. Materials methods Serum sample preparation was based on protein precipitation acetonitrile-methanol mixture. Liraglutide selected internal standard. The mobile phase consisted 0.3% formic acid water acetonitrile. stationary represented by Phenomenex Kinetex C18 chromatographic column 100×3.0 mm, 5 μm, 100 Å. Ionization liraglutide performed positive electrospray mode. Detection carried out multiple reaction monitoring mode (MRM). Results demonstrated accuracy precision, relative error standard deviation values less than 15% across all quality control levels. confirmed analytical ranges were 0.50–200.00 ng/mL 1.00–800.00 ng/mL. Over 3.400 volunteer samples analyzed part Compared ELISA method, proposed provides higher selectivity reproducibility measurements. Conclusions has been developed that reproducible blood validated accordance EAEU requirements successfully applied studies GP40331 (GEROPHARM LLC, Russia). suitable conducting pharmacokinetic other preparations.

Язык: Английский

Процитировано

0